Galectin Therapeutics Inc. (GALT)

[Amatuer17]

The level of risk in NASH studies

AGN acquired Tobira for $1.65 Billion with hopes of getting leg up in NASH

However the P2b results NASH-FX are ambiguous - after 2 years the drug did not perform better than placebo. After 1 year - it showed better results compared to placebo.

GALT NASH-FX trial failed as well. What are chances of NASH-CX showing decent-good-excellent results?

In my view - very low. However even if they showed decent results - a BO possibility is big - simply because there are only 3 trials in this space including GALT. Other BP would like to get head-start in this space without starting from scratch (like AGN)
A successful P2 will provide much low risk entry.

We are very close to unveiling of truth and opportunity/bust.
If results are not good we will drop 86% like VSAR

New Data from CENTAUR Phase 2b Clinical Study Supports Continued Development of Cenicriviroc (CVC) in Ongoing Phase 3 AURORA Trial
https://finance.yahoo.com/news/data-centaur-phase-2b-clinical-120000624.htmlhttps://finance.yahoo.com/news/data-centaur-phase-2b-clinical-120000624.html